Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Products under Development by Stage of Development | 7 | 1 |
| Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Products under Development by Therapy Area | 8 | 1 |
| Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Products under Development by Indication | 9 | 1 |
| Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Products under Development by Companies | 12 | 2 |
| Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Therapeutics Assessment | 14 | 6 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 2 |
| Assessment by Molecule Type | 18 | 2 |
| Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Companies Involved in Therapeutics Development | 20 | 6 |
| Crescendo Biologics Limited | 20 | 1 |
| Exicure, Inc. | 21 | 1 |
| Novartis AG | 22 | 1 |
| Teva Pharmaceutical Industries Ltd. | 23 | 1 |
| UCB S.A. | 24 | 1 |
| Vipergen ApS | 25 | 1 |
| Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Drug Profiles | 26 | 10 |
| Antisense Oligonucleotide to Antagonize IL-17RA for Inflammatory Disorders Drug Profile | 26 | 1 |
| bimekizumab Drug Profile | 27 | 1 |
| CB-001 Drug Profile | 28 | 1 |
| E-34935 Drug Profile | 29 | 1 |
| E-35018 Drug Profile | 30 | 1 |
| E-35762 Drug Profile | 31 | 1 |
| E-36041 Drug Profile | 32 | 2 |
| Recombinant Protein to Inhibit IL-17A for Psoriasis Drug Profile | 34 | 1 |
| Small Molecules to Antagonize IL-17A for Inflammatory and Autoimmune Diseases Drug Profile | 35 | 1 |
| Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Dormant Projects | 36 | 1 |
| Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Featured News &Press Releases | 37 | 4 |
| Jun 10, 2016: UCB s bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis | 37 | 1 |
| Jun 08, 2016: UCB presents Phase 1b data on Bimekizumab at the Annual European Congress of Rheumatology (EULAR 2016) | 38 | 1 |
| Sep 01, 2013: Vipergen presents first discovery of small molecule IL-17A antagonists | 38 | 1 |
| Apr 01, 2013: Ensemble Therapeutics To Present Preclinical Data On IL-17A Inhibitors At 245th ACS National Meeting | 39 | 1 |
| Nov 12, 2012: Ensemble Therapeutics Presents Oral Efficacy Of Small Molecule Targeting IL-17 For Inflammation In Preclinical Studies | 39 | 1 |
| Oct 29, 2012: Ensemble Therapeutics To Present Poster On Interleukin-17 At 2012 ACR Annual Meeting | 40 | 1 |
| Appendix | 41 | 2 |
| Methodology | 41 | 1 |
| Coverage | 41 | 1 |
| Secondary Research | 41 | 1 |
| Primary Research | 41 | 1 |
| Expert Panel Validation | 41 | 1 |
| Contact Us | 41 | 1 |
| Disclaimer | 42 | 1 |